Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies (S37.003)

Andrew Hershey; Christina Szperka; Piero Barbanti; Patricia Pozo-Rosich; Thomas Li; Suzy-Erin Collins; Juline Bryson; Yoel Kessler; Yael Carmeli Schwartz; Verena Ramirez Campos; Xiaoping Ning

doi:10.1212/wnl.0000000000214996

June 9, 2026Neurology

Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies (S37.003)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate how effective and safe fremanezumab is for treating episodic and chronic migraines in younger populations.
Conducted two randomized, double-blind, placebo-controlled phase 3 studies.
Involved children and adolescents diagnosed with episodic and chronic migraine.
Studies registered under NCT04458857 and NCT04464707.
Fremanezumab showed significant efficacy in reducing migraine frequency among participants in both studies.
Safety profile was consistent with expectations, with manageable side effects reported.

Implication

Randomized trial evaluates efficacy and safety of fremanezumab for migraine treatment in children and adolescents, indicating positive outcomes.

Abstract

To evaluate the efficacy and safety of fremanezumab in children and adolescents with episodic (EM; NCT04458857) or chronic migraine (CM; NCT04464707).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hershey et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055d15 https://doi.org/10.1212/wnl.0000000000214996

View Full Paper

Ask AI

Bookmark

Share

Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies (S37.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies (S37.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading